The present invention is related to alkynyl aryl carboxamides of Formula (I') and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia-hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of alkynyl aryl carboxamides of Formula (I') to modulate, notably to inhibit the activity of PTPs. (I') A is a C.sub.2-C.sub.15 alkynyl, C.sub.2-C.sub.6-alkynyl aryl, C.sub.2-C.sup.6-alkynyl heteroaryl. Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group; n is either 0 or 1. Cy' is an aryl., which may optionally be fused by a 3-8 membered cycloalkyl. R.sup.1 and R.sup.2 are independently from each other is selected from the group consisting of hydrogen or (C.sub.1-C.sub.6)alkyl. R.sup.4and R.sup.5 are each independently from each other selected from the group consisting of H, hydroxy. C.sub.1-C.sub.6 alkyl, carboxy, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.3 alkyl carboxy, C.sub.2-C.sub.3 alkenyl carboxy, C.sub.2-C.sub.3 alkynyl carboxy, amino or R.sup.4 and R.sup.5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R.sup.4 or R.sup.5 is not a hydrogen or C.sub.1-C.sub.6 alkyl.